Navigation Links
Preclinical study of a new brain tumor therapy

Scientists have devised a strategy to treat tumors by selectively targeting and killing the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM). This is the most aggressive form of brain tumour, growing very quickly before symptoms are experienced and killing most patients within a year of diagnosis.

Working in mice, Alexander Levitzki and colleagues (of The Hebrew University of Jerusalem and Ludwig-Maximilians-University in Munich) took advantage of previous research that showed how to distinguish between cancerous and healthy cells through the detection of molecules known as epidermal growth factor receptors (EGFR). The glioblastoma cells overexpress EGFR (that is, in comparison with normal brain cells, they have many more of these molecules on their surface). The scientists then selected a type of genetic material (a nucleic acid) associated with viral infections and linked it to a compound that could bind to EGFR. As a result of the defence mechanisms that have evolved to protect mammalian cells from viruses, cells are programmed to die once they take up this particular nucleic acid. The treatment therefore eliminates the tumor cells but avoids damage to the normal brain tissue.

The researchers found that the treatment was effective in mice implanted with human brain tumor cells that overexpressed EGFR. The treatment could eliminate established cancers and there was no evidence of recurrence: the mice remained cancer free for over a year. It is more difficult to cure cancer in humans than cancer in mice, but the results are encouraging. In his Perspective article accompanying the study, Robert Weil of the Brain Tumor Institute at the Cleveland Clinic Foundation suggests that the approach deserves to be "fast-tracked to the clinic" given the lack of effective treatments for GBM. There are few existing options aside from chemotherapy and surg
'"/>

Source:Public Library of Science


Page: 1 2

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
Breaking Biology News(10 mins):Lifelong memories linked to stable nerve connections 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Sakayu Shimizu of Kyoto University recipient of 2009 Enzyme Engineering Award 9960 1Sakayu Shimizu of Kyoto University recipient of 2009 Enzyme Engineering Award 9960 2Regulatory role of key molecule discovered at Hebrew U 9958 1MedTrust Online Surpasses 5 000 Registered Users and Adds Dr Henry Friedman to Oncology Advisory Board 14120 1MedTrust Online Surpasses 5 000 Registered Users and Adds Dr Henry Friedman to Oncology Advisory Board 14120 2
... scientists, including a team from The University ... (IMB), is a step closer to the next generation of...comprehensive analysis of the human and mouse tran...nd IMB researcher Professor David Hume said transc... the genome by a cell at any given time. , "Esse...
...rnational Rice Research Institute (IRRI) is workin...South East Asian Nations (ASEAN) to develop a seri... in the region. , When implemented, the indicators...e environmental impact of its rice production with...blems or improve on existing practices. It,s the f...
... isn,t really that sluggish after all. So says the...e creature,s behavior in the wild, which was just ...l Bulletin. , The new research is significant bec...dibranch mollusc species found in the shallow nort...of the how the brain controls behavior, a field kn...
Other Biology News:Learning the language of DNA 2A cleaner, greener rice industry 2The secret lives of sea slugs 2
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
...n collaboration with the Chinese Academy of Scienc...tation of molecules on a fixed surface to understa...rotor-based machinery at nanoscale level. , The...ch play an important part in machines like electri...logy at the atomic scale is to replicate this prop...
...RCROSS, Ga., May 27 Immucor, Inc. (Nasdaq: BLUD...ent-reagent systems to the blood transfusion indus...r agreement with Alverno Clinical Laboratories, LL... integrated delivery systems in the nation, servin...r the agreement, Alverno is standardizing pre-tran...
...rst clinical study evaluating DUROS(R) continuous ...diabetes , , HAYWARD, Calif., May 27 Intarcia Th...linical data from a phase 1b study of ITCA 650 (DU...reatment of type 2 diabetes as a late-breaker at t...ciation in New Orleans, LA (June 5-9, 2009). The s...
Other Biology Technology:Immucor and Alverno Clinical Laboratories Sign Five-Year Automation Agreement 2Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions 2Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions 3
cAMP Competitive immunoassay Assay Kit, HTRF from Cisbio
...in filters allow for the rapid isolation of DNA fr...ice in the spin filter, centrifuge for 3 minutes, ...s no need to melt agarose or use any special buff...ange, primer removal from PCR reactions, and remov...
Human Atherosclerosis Antibody Array I Kit, ChemiArray, 20 cytokines per membrane from CHEMICON
High-Binding EIA 96 Well Strip Plates from Cayman Chemical
Biology Products: